CH 4051

Drug Profile

CH 4051

Alternative Names: CH-4051; L-CH-1504

Latest Information Update: 27 Jun 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of South Alabama
  • Developer Lundbeck A/S
  • Class Anti-inflammatories
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Autoimmune disorders; Rheumatoid arthritis

Most Recent Events

  • 24 Jun 2014 Chelsea Therapeutics has been acquired and merged into Lundbeck A/S
  • 31 May 2012 Chelsea Therapeutics completes the phase II MOTION trial in Rheumatoid arthritis (treatment-resistant) in the US, Bulgaria and the Czech Republic (NCT01116141)
  • 31 May 2012 Suspended - Phase-I for Autoimmune disorders (in volunteers) in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top